Trial Profile
Post-marketing surveillance for refractory uveoretinitis associated with Behcet's disease under Remicade treatment
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Apr 2020
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Behcet's syndrome; Uveoretinitis
- Focus Adverse reactions; Therapeutic Use
- Acronyms BRIGHT
- Sponsors Mitsubishi Tanabe Pharma Corporation
- 15 Jun 2017 New trial record